ImmunoCellular Therapeutics plans to price public offering of shares

Lazard Capital Markets helps finance clinical development of ICT-107

By Devika Patel

Knoxville, Tenn., Oct. 17 - ImmunoCellular Therapeutics, Ltd. plans to price a public offering of common stock and warrants, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Lazard Capital Markets is the sole bookrunning manager.

Proceeds will be used for clinical development of ICT-107 and general corporate purposes, including research and development activities.

ImmunoCellular is a Woodland Hills, Calif.-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.